Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Gemini Therapeutics Inc (GMTX)

Gemini Therapeutics Inc (GMTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Gemini Therapeutics Inc 297 Boston Post Road #248 Wayland MA 01778 USA

www.geminitherapeutics.com P: 617-401-4400

Description:

Gemini Therapeutics Inc. is a clinical stage precision medicine company. It engages in developing novel therapeutic compounds to treat genetically defined age-related macular degeneration. The company's lead candidate principally includes GEM103. Its pipeline includes recombinant proteins, gene therapies and monoclonal antibodies. Gemini Therapeutics Inc., formerly known as FS Development Corp., is based in CAMBRIDGE, Mass.

Key Statistics

Overview:

Market Capitalization, $K 58,493
Enterprise Value, $K -72,957
Shares Outstanding, K 43,328
Annual Sales, $ 0 K
Annual Net Income, $ -71,870 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -3,280 K
60-Month Beta -0.12
% of Insider Shareholders 12.90%
% of Institutional Shareholders 75.42%
Float, K 37,739
% Float 87.10%
Short Volume Ratio 0.50

Growth:

1-Year Return -53.13%
3-Year Return 0.00%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.08 on 11/10/22
Next Earnings Date 11/21/22
Earnings Per Share ttm -1.00
EPS Growth vs. Prev Qtr 50.00%
EPS Growth vs. Prev Year 81.40%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-10 on 12/30/22

GMTX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -38.78%
Return-on-Assets % -35.88%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 0.56
Book Value/Share 2.42
Interest Coverage -32.27
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar